TMPO Antibodies

Lamina-associated polypeptide 2, isoform alpha (TMPO)

May be involved in the structural organization of the nucleus and at the post-mitotic nuclear assembly. Plays an important role, together with LMNA, in the nuclear anchorage of RB1.

.

Gene Information

Human
Gene Name:	TMPO
Uniprot:	P42166
Entrez:	7112

Family

Belongs to:
LEM family

Alternative Names

CMD1T; lamina-associated polypeptide 2; LAP2PRO0868; LEM domain containing 4; LEMD4; MGC61508; Thymopoietin isoform alpha; Thymopoietin; Thymopoietin, isoforms beta/gamma; Thymopoietin-related peptide isoform alpha; Thymopoietin-related peptide isoforms beta/gamma; TMPO; TP alpha; TP beta/gamma; TP; TPRP isoform alpha; TPRP isoforms beta/gamma

Molecular Weight

Mass (kDA):
75.492 kDA

Genomic Context

Human
Location:	12q23.1
Sequence:	12; NC_000012.12 (98515573..98550351)

Tissue Specificity

Expressed in many tissues. Most abundant in adult thymus and fetal liver.

Subcellular Localizations

Nucleus. Chromosome. Expressed diffusely throughout the nucleus.

Diseases

• Neoplasms
• Malignant Neoplasms
• Vertigo
• Cardiomyopathy, Familial Idiopathic
• Malignant Paraganglionic Neoplasm
• Cardiomyopathy, Dilated
• Cardiomyopathies
• Kidney Diseases
• Non-neoplastic Disorder
• Diabetic Nephropathy
• Melanoma
• Weakness
• Infectious Mononucleosis

• Neoplasms, Experimental
• Werner Syndrome
• Hematopoietic Neoplasms
• Premature Aging Syndrome
• Malignant Neoplasm Of Lung
• Carcinoma
• Multiple Myeloma

Interacting Proteins

• LMNA

Pathways

• Localization
• Pathogenesis
• Mitosis
• Cell Death
• Cell Cycle
• Transport
• Cell Proliferation
• Aging
• Nuclear Envelope Organization
• Dna Repair

• Mrna Splicing
• Translation
• Telomere Maintenance
• Protein Denaturation
• Excretion

PTMs

• Oxidation

• Phosphorylation

Research Areas

• DNA Repair
• DNA replication, Transcription, Translation and Splicing

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/TMPO

Boster Bio - Best Uses Of The TMPO Marker

Boster bio relies on high-affinity primary antibody as its cornerstone. High-affinity antibodies are able to quickly and anonymously identify vaccination histories. Physicians could quickly and anonymously review patients' vaccination histories using a new marker. The question of how to use TMPO markers is complicated and requires guidance. Here are some tips to optimize your experiments. This article may answer some of the questions you have.

The TMPO Marker could be used to quickly and anonymously detect patient vaccination history

It can be difficult to keep track the patient's vaccination history, especially when paperwork is lost or stolen. Without accurate records, parents may forget that a child is up to date on vaccinations. MIT researchers have developed a method to anonymously record the vaccination history for a patient. The team developed an invisible dye that can be detected under the skin and can last for five years.

The TMPO Marker can detect antibodies against COVID-19 and SARS/CoV-2 viruses. This test could help medical professionals confirm a patient's vaccination history without requiring them to present a vaccine card. Businesses could use this technology to screen their employees using an honor system. A new blood test could soon be available. This will allow patients to check their vaccination status while they are waiting to board a plane or take part in a sporting event.

The CDC has established the Vaccine Adverse Event Reporting System (VAERS) in 1990. Its purpose is early detection of adverse events related to vaccines. The system currently receives 30,000 reports a year. About 10 to 15% of these reports describe serious medical conditions. The VAERS is an excellent tool for healthcare workers as well as researchers. However, it has its limitations. There are very few unvaccinated child in the VSD databank. The data also comes from actual medical practice. This makes it difficult for researchers and healthcare workers to evaluate and control.

The mRNA/lipoplex delivery platform is able to deliver the vaccine to patients' tissue using both cationic and neutron lipids. Because the body absorbs the vaccine differently depending on the ratio of lipid-to–mRNA, cationic particles targeted the lung while neutral particles targeted secondary lymphoid and bone marrow tissues. In mouse models, the level of lipids to mRNA was high enough in order to cause a remarkable decrease in tumour size.

Steven Boster

Dr. Steven Boster has passed away on June 26, 2022. He was a lifelong resident of the Twin Cities, a graduate of the University of Minnesota College of Veterinary Medicine and Concordia Hall Staunton. He is survived his 2 daughters, Crystal Boster (Crystal Peck) and 4 brothers, Jack Blanton (Sandra Blanton) and Lisa Milton (Liz Milton), as well as many nieces and nephews.

Primary antibodies of high-affinity

Secondary antibodies are polyclonal antibodies with high affinity. They are produced with an additional purification step to remove off-target species. This further reduces species cross-reactivity while increasing the specificity of antibodies. Secondary antibodies are named according to the host, target antigen, and purification grade. Specific secondary antibodies that are Fab specific should be used in conjunction with primary antibodies from mice. However, monoclonal monoclonal immune antibodies can be produced using polyclonal antibodies against mouse immunoglobulin.

The EASINESS method was applied to increase the binding affinity of 18A4HuscFv with the target protein. This plasmid also contains the error-prone DNA Polymerase (EASINESS). EASINESS was used to measure corresponding affinity in TMP-gradients using this system. The biolayer interferometry screening method was used to screen for the antibodies.

This allows for the generation of antibodies with similar functionalities. The EASINESS method, a novel directed evolutionary system, allows antibody affinity maturation to be accomplished quickly, efficiently, and easily. It is also suitable to small-sized antibodies. EASINESS is also useful for the development high-affinity antibodies. Once validated EASINESS will be a valuable tool for antibody-research.

In addition to reducing the length of dimerizing N-terminal extensions, XTENylated peptides can be fused to antibodies. These XPATs are able to increase the maximum tolerable dose for cynomolgus monkeys. They also have minimal impact on antibody pharmacokinetics. It is possible to engineer the antigens of choice and tailor the affinity of the antibodies.

ALTAs are useful in cancer immunotherapy. This technology takes advantage of the pH difference that exists between the endosomes (and extracellular space) and the cell membrane. This is important because the tumor's microenvironment has a pH between 6.0 and 6.8, which is lower that the pH in healthy tissues. Low vascular perfusion and fermentation can also cause a lower pH in the tumor microenvironment. This is why it is essential to increase the antibody's affinity against tumor cells for their effective use.

Another type of secondary antibody is highly versatile and is useful for multiple labeling experiments. Commercially available secondary antibodies come with diverse labels. Assays are more flexible because of the diversity of labels. They can also be used to amplify signal. Although they don't bind directly to the target protein epitope they do confer specificity. Secondary antibodies also determine how the protein will detect. They can be used for many purposes, including biochemical analysis and clinical diagnosis.

Funding

Australian researchers have discovered a new protein called TMPO that regulates the immune response of cancer patients. The discovery could revolutionize treatment of cancer and other illnesses. It is currently being evaluated as a drug for ovarian carcinoma. This protein is currently found in the blood of cancer patients and may help fight the disease in a new way. Researchers were supported by grants from the National Health and Medical Research Council of Australia (the Chen Family Research Fund), Moderna and Janssen and the Penn Center for Research on Coronavirus and the University of Pennsylvania Perelman School of Medicine.